0 CHECKOUT

Cervical Cancer - Pipeline Review, H1 2015

  • ID: 3338404
  • June 2015
  • Region: Global
  • 308 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • 3SBio Inc.
  • AstraZeneca Plc
  • Genexine, Inc.
  • Kite Pharma, Inc.
  • Nektar Therapeutics
  • Sanofi
  • MORE

This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 3SBio Inc.
  • AstraZeneca Plc
  • Genexine, Inc.
  • Kite Pharma, Inc.
  • Nektar Therapeutics
  • Sanofi
  • MORE

List of Tables
List of Figures
Introduction

REPORT COVERAGE
Cervical Cancer Overview
Therapeutics Development
Pipeline Products for Cervical Cancer - Overview
Pipeline Products for Cervical Cancer - Comparative Analysis
Cervical Cancer - Therapeutics under Development by Companies
Cervical Cancer - Therapeutics under Investigation by Universities/Institutes
Cervical Cancer - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Cervical Cancer - Products under Development by Companies
Cervical Cancer - Products under Investigation by Universities/Institutes
Cervical Cancer - Companies Involved in Therapeutics Development
3SBio Inc.
Admedus Ltd
Advaxis, Inc.
Amorfix Life Sciences Ltd.
Antigen Express, Inc.
Arbor Vita Corporation
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Azaya Therapeutics Incorporated
Cancer Research Technology Limited
Chong Kun Dang Pharmaceutical Corp.
Critical Outcome Technologies Inc.
CZ BioMed Corp
Daiichi Sankyo Company, Limited
EyeGene, Inc.
F. Hoffmann-La Roche Ltd.
Formune S.L.
Genexine, Inc.
Genmab A/S
Genticel S.A.
GlaxoSmithKline Plc
Indian Immunologicals Limited
Inovio Pharmaceuticals, Inc.
ISA Pharmaceuticals B.V.
Karyopharm Therapeutics, Inc.
Kite Pharma, Inc.
LondonPharma Ltd
MedImmune, LLC
MEI Pharma, Inc.
Nanotherapeutics, Inc.
Nektar Therapeutics
Novartis AG
Oncobiologics, Inc.
Otsuka Holdings Co., Ltd.
Redbiotec AG
Rexahn Pharmaceuticals, Inc.
Sanofi
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Shantha Biotechnics Limited
Sirnaomics, Inc.
Taiho Pharmaceutical Co., Ltd.
Theravectys S.A.
Vaccibody AS
VLPbio
Zeria Pharmaceutical Co Ltd
Zydus Cadila Healthcare Limited
Cervical Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(tegafur + gimeracil + oteracil) - Drug Profile
ADXS-HPV - Drug Profile
AEH-10p - Drug Profile
AMF-3d19 - Drug Profile
aminolevulinic acid hydrochloride - Drug Profile
Antisense Oligonucleotides for Cervical Cancer - Drug Profile
Aptamer to Target HPV E7 Protein for Cervical Cancer - Drug Profile
artemether - Drug Profile
AV-203 - Drug Profile
AVC-7 - Drug Profile
AZD-1775 - Drug Profile
AZD-5363 - Drug Profile
bevacizumab - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
BLI-1004 - Drug Profile
BPR-1K653 - Drug Profile
buparlisib hydrochloride - Drug Profile
Cell Therapy for Cervical Carcinoma - Drug Profile
Cell Therapy for HPV Associated Cancers - Drug Profile
Cell Therapy to Target HPV-16 E6 Protein for Cancer - Drug Profile
Cell Therapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer - Drug Profile
CerviVax - Drug Profile
Cervlysis - Drug Profile
CIGB-228 - Drug Profile
CIGB-300 - Drug Profile
CKD-12201 - Drug Profile
COTI-2 - Drug Profile
crocetin - Drug Profile
docetaxel liposomal - Drug Profile
durvalumab + tremelimumab - Drug Profile
EDA-HPVE7 - Drug Profile
EG-HPV - Drug Profile
etirinotecan pegol - Drug Profile
everolimus - Drug Profile
GSK-2849330 - Drug Profile
GX-188E - Drug Profile
human papillomavirus vaccine - Drug Profile
human papillomavirus vaccine - Drug Profile
human papillomavirus vaccine - Drug Profile
human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar - Drug Profile
HuMax-TF-ADC - Drug Profile
INO-3112 - Drug Profile
ISA-101 - Drug Profile
Lovaxin S - Drug Profile
mapatumumab - Drug Profile
ME-344 - Drug Profile
nimotuzumab - Drug Profile
NTCP-02 - Drug Profile
OPB-111001 - Drug Profile
OTAC-DCtag - Drug Profile
patritumab - Drug Profile
pazopanib hydrochloride - Drug Profile
Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Oncology - Drug Profile
Peptides to Inhibit Bcl-x and MCL-1 for Oncology - Drug Profile
ProCervix - Drug Profile
RA-190 - Drug Profile
RBT-201 - Drug Profile
RX-3117 - Drug Profile
S-009131 - Drug Profile
SAR-408701 - Drug Profile
selinexor - Drug Profile
Small molecule to Inhibit Bcl-x Protein and MCL-1 for Oncology - Drug Profile
Small Molecules for Cervival Cancer - Drug Profile
SSS-08 - Drug Profile
STP-909 - Drug Profile
TA-CIN - Drug Profile
Tenacinol - Drug Profile
TF-011 Monomethyl Auristatin E - Drug Profile
trametinib dimethyl sulfoxide + uprosertib - Drug Profile
Triapine - Drug Profile
Vaccine for Cervical and Head and Neck Cancers - Drug Profile
Vaccine for Cervical Cancer - Drug Profile
Vaccine for Cervical Cancer - Drug Profile
vaccine for cervical cancer - Drug Profile
Vaccine for Cervical Cancer and Genital Warts - Drug Profile
Vaccine for Cervical Cancer, Head And Neck Cancer - Drug Profile
Vaccine for HPV Associated Cancers - Drug Profile
Vaccine for Ovarian Cancer and Cervical Cancer - Drug Profile
Vaccine to Target HPV E7 Protein for Cervical Cancer - Drug Profile
Vaccine to Target HPV Minor Capsid Protein L2 for Cervical Cancer - Drug Profile
VB-1016 - Drug Profile
Vvax-001 - Drug Profile
Z-100 - Drug Profile
Cervical Cancer - Recent Pipeline Updates
Cervical Cancer - Dormant Projects
Cervical Cancer - Discontinued Products
Cervical Cancer - Product Development Milestones
Featured News & Press Releases

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Cervical Cancer, H1 2015
Number of Products under Development for Cervical Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2015
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Cervical Cancer - Pipeline by 3SBio Inc., H1 2015
Cervical Cancer - Pipeline by Admedus Ltd, H1 2015
Cervical Cancer - Pipeline by Advaxis, Inc., H1 2015
Cervical Cancer - Pipeline by Amorfix Life Sciences Ltd., H1 2015
Cervical Cancer - Pipeline by Antigen Express, Inc., H1 2015
Cervical Cancer - Pipeline by Arbor Vita Corporation, H1 2015
Cervical Cancer - Pipeline by AstraZeneca Plc, H1 2015
Cervical Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015
Cervical Cancer - Pipeline by Azaya Therapeutics Incorporated, H1 2015
Cervical Cancer - Pipeline by Cancer Research Technology Limited, H1 2015
Cervical Cancer - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015
Cervical Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2015
Cervical Cancer - Pipeline by CZ BioMed Corp, H1 2015
Cervical Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2015
Cervical Cancer - Pipeline by EyeGene, Inc., H1 2015
Cervical Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Cervical Cancer - Pipeline by Formune S.L., H1 2015
Cervical Cancer - Pipeline by Genexine, Inc., H1 2015
Cervical Cancer - Pipeline by Genmab A/S, H1 2015
Cervical Cancer - Pipeline by Genticel S.A., H1 2015
Cervical Cancer - Pipeline by GlaxoSmithKline Plc, H1 2015
Cervical Cancer - Pipeline by Indian Immunologicals Limited, H1 2015
Cervical Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H1 2015
Cervical Cancer - Pipeline by ISA Pharmaceuticals B.V., H1 2015
Cervical Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2015
Cervical Cancer - Pipeline by Kite Pharma, Inc., H1 2015
Cervical Cancer - Pipeline by LondonPharma Ltd, H1 2015
Cervical Cancer - Pipeline by MedImmune, LLC, H1 2015
Cervical Cancer - Pipeline by MEI Pharma, Inc., H1 2015
Cervical Cancer - Pipeline by Nanotherapeutics, Inc., H1 2015
Cervical Cancer - Pipeline by Nektar Therapeutics, H1 2015
Cervical Cancer - Pipeline by Novartis AG, H1 2015
Cervical Cancer - Pipeline by Oncobiologics, Inc., H1 2015
Cervical Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2015
Cervical Cancer - Pipeline by Redbiotec AG, H1 2015
Cervical Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2015
Cervical Cancer - Pipeline by Sanofi, H1 2015
Cervical Cancer - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2015
Cervical Cancer - Pipeline by Shantha Biotechnics Limited, H1 2015
Cervical Cancer - Pipeline by Sirnaomics, Inc., H1 2015
Cervical Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2015
Cervical Cancer - Pipeline by Theravectys S.A., H1 2015
Cervical Cancer - Pipeline by Vaccibody AS, H1 2015
Cervical Cancer - Pipeline by VLPbio, H1 2015
Cervical Cancer - Pipeline by Zeria Pharmaceutical Co Ltd, H1 2015
Cervical Cancer - Pipeline by Zydus Cadila Healthcare Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Cervical Cancer Therapeutics - Recent Pipeline Updates, H1 2015
Cervical Cancer - Dormant Projects, H1 2015
Cervical Cancer - Dormant Projects (Contd..1), H1 2015
Cervical Cancer - Dormant Projects (Contd..2), H1 2015
Cervical Cancer - Dormant Projects (Contd..3), H1 2015
Cervical Cancer - Discontinued Products, H1 2015

List of Figures

Number of Products under Development for Cervical Cancer, H1 2015
Number of Products under Development for Cervical Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

- 3SBio Inc.
- Admedus Ltd
- Advaxis, Inc.
- Amorfix Life Sciences Ltd.
- Antigen Express, Inc.
- Arbor Vita Corporation
- AstraZeneca Plc
- AVEO Pharmaceuticals, Inc.
- Azaya Therapeutics Incorporated
- Cancer Research Technology Limited
- Chong Kun Dang Pharmaceutical Corp.
- Critical Outcome Technologies Inc.
- CZ BioMed Corp
- Daiichi Sankyo Company, Limited
- EyeGene, Inc.
- F. Hoffmann-La Roche Ltd.
- Formune S.L.
- Genexine, Inc.
- Genmab A/S
- Genticel S.A.
- GlaxoSmithKline Plc
- Indian Immunologicals Limited
- Inovio Pharmaceuticals, Inc.
- ISA Pharmaceuticals B.V.
- Karyopharm Therapeutics, Inc.
- Kite Pharma, Inc.
- LondonPharma Ltd
- MedImmune, LLC
- MEI Pharma, Inc.
- Nanotherapeutics, Inc.
- Nektar Therapeutics
- Novartis AG
- Oncobiologics, Inc.
- Otsuka Holdings Co., Ltd.
- Redbiotec AG
- Rexahn Pharmaceuticals, Inc.
- Sanofi
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Shantha Biotechnics Limited
- Sirnaomics, Inc.
- Taiho Pharmaceutical Co., Ltd.
- Theravectys S.A.
- Vaccibody AS
- VLPbio
- Zeria Pharmaceutical Co Ltd
- Zydus Cadila Healthcare Limited

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Eli Lilly and Company
  • Roche Diagnostics Ltd.
  • Aviva Plc.
  • Merck & Co., Inc.
  • GlaxoSmithKline PLC
  • CSL Limited